FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Thomas Fleming

Research Profile

Chemicals & Drugs

Disorders

Living Beings

Physiology

Geographic Areas

Concepts & Ideas

Procedures

Epidemiologic Research Designs

Activities & Behaviors

Consumer Product Safety

Co-author Network

Publications

TOP 3
J Brooks Jackson; Teresa Parsons; Philippa Musoke; Clemensia Nakabiito; Deborah Donnell; Thomas Fleming; Mark Mirochnick; Lynne Mofenson; Mary Glenn Fowler; Francis Mmiro; Laura A Guay
Association of cord blood nevirapine concentration with reported timing of dose and HIV-1 transmission.
Avinash K Shetty; Hoosen M Coovadia; Mark Mirochnick; Yvonne Maldonado; Lynne M Mofenson; Susan H Eshleman; Thomas Fleming; Lynda Emel; Kathy George; David A Katzenstein; Jennifer Wells; Charles Chiedza Maponga; Anthony Mwatha; Samuel Adeniyi Jones; Salim S Abdool-Karim; Mary T Bassett
Safety and trough concentrations of nevirapine prophylaxis given daily, twice weekly, or weekly in breast-feeding infants from birth to 6 months.
J Brooks Jackson; Philippa Musoke; Thomas Fleming; Laura A Guay; Danstan Bagenda; Melissa Allen; Clemensia Nakabiito; Joseph Sherman; Paul M Bakaki; Maxensia Owor; Constance Ducar; Martina Deseyve; Anthony Mwatha; Lynda Emel; Corey Duefield; Mark Mirochnick; Mary Glenn Fowler; Lynne Mofenson; Paolo Miotti; Maria Gigliotti; Dorothy Bray; Francis Mmiro
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Thomas Fleming (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2006: J Brooks Jackson; Teresa Parsons; Philippa Musoke; Clemensia Nakabiito; Deborah Donnell; Thomas Fleming; Mark Mirochnick; Lynne Mofenson; Mary Glenn Fowler; Francis Mmiro; Laura A Guay
Association of cord blood nevirapine concentration with reported timing of dose and HIV-1 transmission.
AIDS (London, England) 2006;20(2):217-22.
2003: Avinash K Shetty; Hoosen M Coovadia; Mark Mirochnick; Yvonne Maldonado; Lynne M Mofenson; Susan H Eshleman; Thomas Fleming; Lynda Emel; Kathy George; David A Katzenstein; Jennifer Wells; Charles Chiedza Maponga; Anthony Mwatha; Samuel Adeniyi Jones; Salim S Abdool-Karim; Mary T Bassett
Safety and trough concentrations of nevirapine prophylaxis given daily, twice weekly, or weekly in breast-feeding infants from birth to 6 months.
Journal of acquired immune deficiency syndromes (1999) 2003;34(5):482-90.
2003: J Brooks Jackson; Philippa Musoke; Thomas Fleming; Laura A Guay; Danstan Bagenda; Melissa Allen; Clemensia Nakabiito; Joseph Sherman; Paul M Bakaki; Maxensia Owor; Constance Ducar; Martina Deseyve; Anthony Mwatha; Lynda Emel; Corey Duefield; Mark Mirochnick; Mary Glenn Fowler; Lynne Mofenson; Paolo Miotti; Maria Gigliotti; Dorothy Bray; Francis Mmiro
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.
Lancet 2003;362(9387):859-68.
2002: Susan H Eshleman; Laura A Guay; Thomas Fleming; Anthony Mwatha; Martin R Mracna; Graziella Becker-Pergola; Philippa Musoke; Francis Mmiro; J Brooks Jackson
Survival of Ugandan infants with subtype A and D HIV-1 infection (HIVNET 012).
Journal of acquired immune deficiency syndromes (1999) 2002;31(3):327-30.
2001: Susan H Eshleman; Martin R Mracna; Laura A Guay; Martina Deseyve; S Cunningham; Mark Mirochnick; Philippa Musoke; Thomas Fleming; M Glenn Fowler; Lynne M Mofenson; Francis Mmiro; J Brooks Jackson
Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012).
AIDS (London, England) 2001;15(15):1951-7.
2001: Susan H Eshleman; Graziella Becker-Pergola; Martina Deseyve; Laura A Guay; Martin R Mracna; Thomas Fleming; S Cunningham; Philippa Musoke; Francis Mmiro; J Brooks Jackson
Impact of human immunodeficiency virus type 1 (hiv-1) subtype on women receiving single-dose nevirapine prophylaxis to prevent hiv-1 vertical transmission (hiv network for prevention trials 012 study).
The Journal of infectious diseases 2001;184(7):914-7.
1999: Laura A Guay; Philippa Musoke; Thomas Fleming; Danstan Bagenda; Melissa Allen; Clemensia Nakabiito; J Sherman; Paul M Bakaki; Constance Ducar; Martina Deseyve; Lynda Emel; Mark Mirochnick; Mary Glenn Fowler; Lynne Mofenson; Paolo Miotti; K Dransfield; D Bray; Francis Mmiro; J Brooks Jackson
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial.
Lancet 1999;354(9181):795-802.
1999: Philippa Musoke; Laura A Guay; Danstan Bagenda; Mark Mirochnick; Clemensia Nakabiito; Thomas Fleming; T Elliott; S Horton; K Dransfield; J W Pav; A Murarka; Melissa Allen; Mary Glenn Fowler; Lynne Mofenson; David L Hom; Francis Mmiro; J Brooks Jackson
A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006).
AIDS (London, England) 1999;13(4):479-86.